Pirfenidone is an oral anti-inflammatory and anti-fibrotic drug that was approved for the treatment of idiopathic pulmonary fibrosis (IPF) in 2014. touchRESPIRATORY caught up with Prof. Jürgen Behr (Ludwig-Maximilians-University of Munich, Munich, Germany) to discuss the aims, design, and findings from his analysis of studies comparing the efficacy of pirfenidone in advanced vs non-advanced IPF in randomized controlled trials and open-label extension trials.
The abstract ‘Efficacy of pirfenidone in patients with advanced IPF.’ (Abstract number: PA1936) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What were the aims and design of, and definition of advanced IPF in your study? (1:36)
- What were the study findings and what will be their clinical impact? (4:21)
Disclosures: Jürgen Behr discloses consulting for Biogen, Boehringer-Ingelheim, Bristol-Myer-Squibbs, Ferrer, Galapagos, Pliant, Roche and Sanofi/Genzyme; discloses receiving grant/ research support from DFG and BMBF; serving on advisory boards for Biogen, Boehringer-Ingelheim, Bristol-Myer-Squibbs, Ferrer, Galapagos, Pliant, Roche and Sanofi/Genzyme; receiving honoraria from Biogen, Boehringer-Ingelheim, Bristol-Myer-Squibbs, Ferrer, Galapagos, Pliant, Roche and Sanofi/Genzyme; participating in speaker’s bureaus for Astra-Zeneca, Boehringer-Ingelheim, Ferrer, MSD, Novartis and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
